MedPath

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Phase 3
Active, not recruiting
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
Registration Number
NCT04033354
Lead Sponsor
Shanghai Henlius Biotech
Brief Summary

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC who have not previously received systemic treatment.

Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

Arm A (HLX10 arm): HLX10 + chemotherapy (carboplatin nab paclitaxel) Arm B (placebo arm): Placebo + chemotherapy (carboplatin nab paclitaxel) The three stratification factors for randomization include: PD-L1 expression level (Tumor Proportion Scores \[TPS\]≥50%, 50%\>TPS≥1%, TPS\<1%), Asian population (yes or no), NSCLC stage (stage IIIB/IIIC or stage IV), and carboplatin AUC (5 or 6).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
537
Inclusion Criteria
  1. Patients with histologically or cytologically confirmed stage IIIB/IIIC and stage IV (AJCC Edition 8) squamous NSCLC where surgery or radiotherapy cannot be performed.
  2. No known sensitizing EGFR mutations or ALK, ROS1 gene rearrangements.
  3. Major organs are functioning well
  4. Participant must keep contraception
  5. Patients with prior denosumab use who can agree to switch to bisphosphonate therapy for bone metastases in the study.
Exclusion Criteria
  1. Patients with histologically non-squamous NSCLC. Mixed tumors will be classified according to the primary cell type. Patients do not meet the requirements for enrollment if small cell components and neuroendocrine carcinoma components are present. For non-small cell histology, patients meet the requirements for enrollment if squamous components (e.g., adenosquamous) are present.
  2. Patients with known history of severe hypersensitivity to any monoclonal antibody.
  3. Patients with known hypersensitivity to any compositions of carboplatin or nab-paclitaxel.
  4. Pregnant or breastfeeding females.
  5. Patients with a known history of psychotropic drug abuse or drug addiction; or a history of alcohol abuse.
  6. Patients who have other factors that could lead to the early termination of this study based on the investigator's judgment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Acarboplatin and nab paclitaxelHLX10 + chemotherapy (carboplatin nab paclitaxel)
BPlaceboPlacebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
Bcarboplatin and nab paclitaxelPlacebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
AHLX10HLX10 + chemotherapy (carboplatin nab paclitaxel)
Primary Outcome Measures
NameTimeMethod
tumor assessmentBaseline until disease progression or death, whichever occurs first (up to approximately 24months)

Progression-free survival (PFS) (assessed by the independent radiology review committee \[IRRC\] based on Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (92)

Anhui Medical University - The Second Hospital

🇨🇳

Hefei, Anhui, China

The Second Affiliated Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

Daping Hospital

🇨🇳

Chongqing, Chongqing, China

Fujian Medical University Union Hospital

🇨🇳

Fuzhou, Fujian, China

Fuzhou Pulmonary hospital of Fujian

🇨🇳

Fuzhou, Fujian, China

Gansu Wuwei Tumour Hospital

🇨🇳

Wuwei, Gansu, China

The Fifth Affiliared Hospital Sun Yat-Sen University

🇨🇳

Zhuhai, Guangdong, China

Liuzhou Worker's Hospital

🇨🇳

Liuzhou, Guangxi, China

Tangshan People's Hospital

🇨🇳

Tangshan, Hebei, China

The Third Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

the First Affiliated Hospital of Nanchang University

🇨🇳

Nanchang, Jiangxi, China

JSC Evex Clinics, St.Nikolozi Medical Centre

🇬🇪

Kutaisi, Georgia

LLC "VitaMed "

🇷🇺

Moscow, Russian Federation

Oncology and Hematology Associates of Southwest Virginia

🇺🇸

Roanoke, Virginia, United States

Anhui Provincial Hospital

🇨🇳

Hefei, Anhui, China

The First Affiliated Hospital Of Anhui Medical University

🇨🇳

Hefei, Anhui, China

Beijing Friendship Hospital

🇨🇳

Beijing, Beijing, China

Beijing Chaoyang Hospital

🇨🇳

Beijing, Beijing, China

The Second Affiliated Hospital of Army Medical University,PLA

🇨🇳

Chongqing, Chongqing, China

Fujian Provincial Cancer Hospital

🇨🇳

Fuzhou, Fujian, China

The First Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

Liuzhou People's Hospital

🇨🇳

Liuzhou, Guangxi, China

Guangxi Medical University Affiliated Tumor Hospital

🇨🇳

Nanning, Guangxi, China

The People's Hospital of Guangxi Zhuang Autonomous Region

🇨🇳

Nanning, Guangxi, China

The Second Affiliated Hospital of Hainan Medical University

🇨🇳

Haikou, Hainan, China

Cangzhou People's Hospital

🇨🇳

Cangzhou, Hebei, China

Affiliated Hospital of Hebei University

🇨🇳

Baoding, Hebei, China

Jiamusi Cancer Hospital

🇨🇳

Jiamusi, Heilongjiang, China

Harbin Medical University - Tumor Hospital (The Third Affiliated Hospital)

🇨🇳

Ha'erbin, Heilongjiang, China

The First Affiliated Hospital of Xinxiang Medical University

🇨🇳

Xinxiang, Henan, China

Hubei Cancer Hospital

🇨🇳

Wuhan, Hubei, China

The fourth affiliated hospital of Harbin medical university

🇨🇳

Ha'erbin, Heilongjiang, China

Henan Cancer Hospital

🇨🇳

Zhengzhou, Henan, China

The Third Affiliated Hospital of Qiqihar Medical University

🇨🇳

Qiqihar, Heilongjiang, China

Hunan Cancer Hospital

🇨🇳

Changsha, Hunan, China

Xuzhou Central Hospital

🇨🇳

Xuzhou, Jiangsu, China

Jilin Province Cancer Hospital

🇨🇳

Changchun, Jilin, China

China-japan union hospital of jilin university

🇨🇳

Changchun, Jilin, China

Jilin Province People's Hospital

🇨🇳

Changchun, Jilin, China

The second Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, Ningxia, China

The first hospital of Jilin University

🇨🇳

Changchun, Jilin, China

Chifeng Municipal Hospital

🇨🇳

Chifeng, Neimenggu, China

Shandong Linyi Tumor Hospital

🇨🇳

Linyi, Shandong, China

Linyi City People Hospital

🇨🇳

Linyi, Shandong, China

Shandong Cancer Hospital - Internal Medicine

🇨🇳

Jinan, Shandong, China

Shanghai Eastern Hospital /Affliated Eastern Hospital of Ton

🇨🇳

Shanghai, Shanghai, China

West China Hospital, Sichuan University

🇨🇳

Chengdu, Sichuan, China

Shanghai Pulmonary Hospital

🇨🇳

Shanghai, Shanghai, China

Tianjin Medical University Cancer Hospital

🇨🇳

Tianjin, Tianjin, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, Tianjin, China

The Second Affiliated Hospital of Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

Yunnan cancer hospital

🇨🇳

Kunming, Yunnan, China

Sir Run Run Shaw Hospital, Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

High Technology Hospital MedCenter LTD

🇬🇪

Batumi, Georgia

Acad.F.Todua Medical Center - Research Institute of Clinical Medicine LTD

🇬🇪

Tbilisi, Georgia

Institute of Clinical Oncology LTD

🇬🇪

Tbilisi, Georgia

LTD Israeli-Georgian Medical Research Clinic HELSICORE

🇬🇪

Tbilisi, Georgia

Multiprofile Clinic Consilium Medula LTD

🇬🇪

Tbilisi, Georgia

New Hospitals LTD

🇬🇪

Tbilisi, Georgia

Uniwersytecki Szpital Kliniczny w Białymstoku

🇵🇱

Białystok, Poland

Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi

🇵🇱

Łódź, Poland

University Clinic of Headaches

🇷🇺

Moscow, Russian Federation

Scientific Research Center of Oncology LTD

🇬🇪

Tbilisi, Georgia

Budgetary Healthcare Institution of Omsk Region "C

🇷🇺

Omsk, Russian Federation

Limited Liability Company "AV Medical Group"

🇷🇺

Saint Petersburg, Russian Federation

GBUZ Orenburg Regional Clinical Oncology Dispensar

🇷🇺

Orenburg, Russian Federation

First St. Petersburg State Medical University n. a. Pavlov

🇷🇺

Saint Petersburg, Russian Federation

LLC - Strategic Medical systems - Oncology - Oncology

🇷🇺

Saint Petersburg, Russian Federation

PMI "Evromedservice"

🇷🇺

Saint Petersburg, Russian Federation

Ankara University Medical Faculty - Oncology

🇹🇷

Ankara, Turkey

Trakya University Medical Faculty

🇹🇷

Edirne, Turkey

Volgograd Regional Clinical Oncology Dispensary

🇷🇺

Volgograd, Russian Federation

Hacettepe University Medical Faculty - Medical Oncology

🇹🇷

Ankara, Turkey

Istanbul University Cerrahpasa Medical Faculty

🇹🇷

Istanbul, Turkey

Medipol Mega Hospital

🇹🇷

Istanbul, Turkey

Ege University Medical Faculty

🇹🇷

İzmir, Turkey

Izmir Medical Park Hospital - Medical Oncology

🇹🇷

İzmir, Turkey

Kocaeli University Research and Practice Hospital

🇹🇷

Kocaeli, Turkey

Necmettin Erbakan University Meram Medical Faculty

🇹🇷

Konya, Turkey

Inonu University Turgut Ozal Medical Center

🇹🇷

Malatya, Turkey

Komunalnyi zaklad Miska bahato

🇺🇦

Dnipro, Ukraine

Komunalna ustanova "Chernivets

🇺🇦

Chernivtsi, Ukraine

Komunalne nekomertsiine pidpry

🇺🇦

Kharkiv, Ukraine

PE PMC "Acinus"

🇺🇦

Kirovohrad, Ukraine

Medychnyi tsentr "Mriya Med-Servis"

🇺🇦

Kryvyi Rih, Ukraine

Limited Liability Company "Medical Center "Verum"

🇺🇦

Kyiv, Ukraine

Komunalne pidpryiemstvo "Volynskyi oblasnyi medychnyi tsentr onkolohii" Volynskoyi oblasnoyi rady

🇺🇦

Luts'k, Ukraine

Medychnyi tsentr "Onkolaif" LL

🇺🇦

Zaporizhzhia, Ukraine

Zaporozhye Regional Clinical O

🇺🇦

Zaporizhzhia, Ukraine

Peking University First Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath